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Abstract
Background: The high mortality and cardiovascular disease (CVD) burden in patients with end-stage renal disease
(ESRD) is well-documented. Recent literature suggests that acute kidney injury is also associated with CVD. It is
unknown whether patients with incident ESRD due to dialysis-requiring acute kidney injury (AKI-D) are at higher
short-term risk for death and CVD events, compared with incident ESRD patients without preceding AKI-D. Few
studies have examined the impact of recovery from AKI-D on subsequent CVD risk.
Methods: In this retrospective cohort study, we evaluated adult members of Kaiser Permanente Northern California
who initiated dialysis from January 2009 to September 2015. Preceding AKI-D and subsequent outcomes of death
and CVD events (acute coronary syndrome, heart failure, ischemic stroke or transient ischemic attack) were identified
from electronic health records. We performed multivariable Cox regression models adjusting for demographics,
comorbidities, medication use, and laboratory results.
Results: Compared to incident ESRD patients who experienced AKI-D (n = 1865), patients with ESRD not due to AKI-D
(n = 3772) had significantly lower adjusted rates of death (adjusted hazard ratio [aHR] 0.56, 95% CI: 0.47–0.67) and heart
failure hospitalization (aHR 0.45, 0.30–0.70). Compared to AKI-D patients who did not recover and progressed to ESRD,
AKI-D patients who recovered (n = 1347) had a 30% lower adjusted relative rate of death (aHR 0.70, 0.55–0.88).
Conclusions: Patients who transition to ESRD via AKI-D are a high-risk subgroup that may benefit from aggressive
monitoring and medical management, particularly for heart failure. Recovery from AKI-D is independently associated
with lower short-term mortality.
Keywords: Cardiovascular events, Mortality, End-stage renal disease, Dialysis-requiring acute kidney injury, Renal recovery
Background
Patients with end-stage renal disease (ESRD) experience
a high burden of early death and cardiovascular disease
(CVD), particularly within the first year after dialysis ini-
tiation (189 to 382 per 1000 person-years) [1–7].
Furthermore, CVD contributes to > 50% of all ESRD
deaths with known causes [8].
Recent literature suggests that acute kidney injury may
also be associated with increased risk of CVD events [9–
16]. Acute kidney injury is associated with increased in-
flammatory cytokines [17], which may increase risk of
subsequent CVD events [18] via endothelial dysfunction
or plaque rupture [19]. Of note, abrupt decline in kidney
function during the three months before initiating
hemodialysis is a strong, independent risk factor for
early death after ESRD onset [20]. Dialysis-requiring
acute kidney injury (AKI-D) is not an uncommon pre-
cipitant to ESRD [21, 22] and may be an important con-
tributor to the high early mortality rates and excess
CVD risk in incident ESRD patients. However, few stud-
ies have examined outcomes in this ESRD subgroup.
In a diverse, community-based cohort, we examined
the association between AKI-D and short-term death
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and CVD outcomes. We hypothesized that patients with
incident ESRD due to AKI-D are at higher short-term
risk for death and CVD events compared to patients
with incident ESRD that is not attributable to AKI-D,
even after controlling for known vascular risk factors.
Furthermore, we hypothesized that patients who recover
adequate kidney function after AKI-D to discontinue
dialysis would experience better outcomes. Our goal was
to provide insight into the clinical implications of AKI-D
as well as recovery from AKI-D to improve risk stratifi-
cation and guide development of more tailored pre-
ventative strategies.
Methods
Source population
Kaiser Permanente Northern California (KPNC) is a
large, integrated health care delivery system that
currently provides comprehensive inpatient and out-
patient care for > 4.1 million members in the greater San
Francisco Bay Area. Its membership is highly diverse
and representative of the local surrounding and state-
wide population [23], with nearly all aspects of care
captured through KPNC’s electronic medical record system.
This study was approved by the institutional review
boards at KPNC and University of California, San Francisco
(#16–20030). We obtained a waiver of informed consent
given the nature of the study.
Study sample
We identified all adult (age ≥18 years) KPNC members
who developed AKI-D or who initiated chronic
hemodialysis between January 2009 and September 2015
and who had ≥12 consecutive months of health plan
membership and pharmacy benefits before initiation of
renal replacement therapy (RRT) in order to ensure ad-
equate capture of relevant comorbidities and prescrip-
tion medication use. We defined AKI-D as receipt of
RRT during hospitalization in the absence of any
pre-admission RRT (dialysis or transplant). Inpatient
RRT included receipt of peritoneal dialysis, hemodialysis,
and hemofiltration that were identified using Inter-
national Classification of Diseases, Ninth Revision
(ICD-9) procedure codes (54.98, 39.95) and Current
Procedural Terminology codes (90,935, 90,937, 90,945,
90,947, 90,999). We previously demonstrated the accur-
acy of these codes to identify AKI-D across the spectrum
of pre-admission estimated glomerular filtration rate
(eGFR) based on adjudication of medical records by a
board-certified nephrologist in a random sample of 100
patients (positive predictive value 94%) [24]. We ex-
cluded one patient with pre-hospitalization eGFR >
150 mL/min/1.73m2 because of concerns about the ac-
curacy of the value. Patients initiating chronic
hemodialysis without preceding AKI-D were ascertained
through a comprehensive health system ESRD Treat-
ment Registry [21, 22, 25]. For incident ESRD patients
who did not have AKI-D, we studied only hemodialysis
patients because risk factors for early death and CVD
events may differ according to ESRD treatment modal-
ity, and because hemodialysis is the most common initial
modality in the U.S. [8].
Predictor variable
The two primary comparisons were 1) between patients
with incident ESRD due to non-recovery from AKI-D
versus incident ESRD patients who did not have AKI-D
and 2) between AKI-D patients who did versus who did
not recover adequate kidney function to discontinue dia-
lysis. Recovery from AKI-D was defined as being alive
and no longer needing RRT for ≥4 weeks at 90 days after
initiation of acute RRT. We required that patients re-
main alive for ≥4 weeks to reduce potential misclassifica-
tion due to withdrawal of care. To be comprehensive,
recovery could occur during the index hospitalization or
in the outpatient setting after hospital discharge. We
used recovery status at 90 days, as patients are conven-
tionally considered to have ESRD using this cutoff [26].
Follow-up and outcome variables
We focused on short-term clinical outcomes of AKI-D
because we a priori hypothesized that the effect of
AKI-D would gradually fade over time, consistent with
findings regarding the potential effect of acute kidney in-
jury on other outcomes [16]. Starting 90 days after RRT
initiation, patients were censored at health plan disen-
rollment or death up to 365 days. We excluded patients
censored before 90 days post-RRT initiation because
90-day survival was necessary to ascertain recovery from
AKI-D, as well as patients with hospitalizations ≥90 days
after acute RRT initiation.
Primary clinical outcomes included all-cause death,
heart failure, acute coronary syndrome (ACS), and acute
ischemic stroke or transient ischemic attack (TIA) oc-
curring between 90 days and 455 days (i.e., up to one
year later) after RRT initiation using validated diagnosis
codes and algorithms with high positive predictive values
based on data found in comprehensive health plan elec-
tronic medical records (codes available upon request)
[27, 28]. Vital status was based on comprehensive infor-
mation from health plan administrative and hospital dis-
charge databases, member proxy reporting, Social
Security Administration vital status files, and California
state death certificate information [27, 29].
Covariates
We relied primarily on electronic health record data that
were standardized and linked at the patient-level in the
Kaiser Permanente Virtual Data Warehouse [21, 28, 30–
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32]. Demographic and lifestyle characteristics included
age, gender, self-reported race/ethnicity, and tobacco use.
Relevant pre-admission comorbidities (heart failure, cor-
onary disease, ischemic stroke, peripheral artery disease,
atrial fibrillation, mitral/aortic valvular disease, hyperten-
sion, diabetes mellitus, dyslipidemia, prior hospitalized
bleed, thyroid disease, cirrhosis, lung disease, dementia,
and depression) were defined using validated diagnostic or
procedure codes [33]. We ascertained outpatient body
mass index and systolic blood pressure, as well as relevant
outpatient laboratory test results (eGFR using the
CKD-EPI equation, urine dipstick proteinuria,
high-density lipoprotein, low-density lipoprotein, and
hemoglobin levels) and receipt of medications (angioten-
sin converting enzyme inhibitors, angiotensin II receptor
blockers, beta blockers, calcium channel blockers, di-
uretics, aldosterone receptor antagonists, alpha blockers,
antiarrhythmic agents, nitrates, other vasodilators,
non-aspirin antiplatelet agents, low-molecular-weight
heparin, statins, other lipid-lowering agents, anti-diabetic
agents, and non-steroidal anti-inflammatory drugs).
Statistical approach
All analyses were conducted using SAS, version 9.3
(Cary, N.C.). Baseline characteristics were compared
across exposure categories using ANOVA for continuous
variables and χ2 tests for categorical variables.
We calculated crude incidence rates and 95% confi-
dence intervals for outcomes by exposure group. After
confirming no violation of the proportional hazards as-
sumption using visual examination of Kaplan-Meier
curves and ln(−ln) plots and assessment of Schoenfeld re-
siduals, we conducted Cox regression models for each
outcome of interest with adjustment for demographics, to-
bacco use, comorbidities, vital signs, and medication use.
We also conducted sensitivity analyses using AKI-D
patients with a pre-existing eGFR > 24 ml/min/1.73 m2,
which was the 75th percentile threshold for this subset
of our cohort (ESRD due to AKI-D n = 434, ESRD not
due to AKI-D n = 3772, recovered AKI-D n = 942).
Results
Baseline characteristics
We initially identified 13,213 hospitalized patients who
received inpatient RRT and 6414 patients who initiated
chronic hemodialysis as outpatients between January
2009 and September 2015. After applying exclusion cri-
teria, our final sample included 1865 patients with inci-
dent ESRD due to AKI-D (i.e., non-recovery from
AKI-D), 3772 patients with incident ESRD not due to
AKI-D, and 1347 AKI-D patients who recovered within
90 days after RRT initiation.
Compared to incident ESRD patients without AKI-D,
patients with incident ESRD due to AKI-D were older,
more likely to be white, and generally had a higher bur-
den of baseline CVD (Table 1). Compared to AKI-D pa-
tients who did not recover, AKI-D patients who
recovered were younger, more likely to be white, had
higher baseline eGFR, and were less likely to have
pre-existing heart failure and other CVD, hypertension,
diabetes, or dyslipidemia (Table 1).
Outcomes between ESRD due to AKI-D vs. ESRD not due
to AKI-D
In unadjusted analyses, patients with incident ESRD due
to AKI-D had higher all-cause death rates than patients
with incident ESRD who did not experience AKI-D
(Table 2). Patients with incident ESRD due to AKI-D
also had significantly higher crude heart failure
hospitalization and ACS rates but no significant differ-
ences in stroke/TIA.
In multivariable analyses, compared to patients with
incident ESRD due to AKI-D, those with incident ESRD
not due to AKI-D had a significantly lower adjusted rate
of all-cause death (adjusted hazard ratio [aHR] 0.56, 95%
CI 0.47–0.67) (Fig. 1). After adjustment for potential
confounders, ESRD not due to AKI-D was also associ-
ated with a lower adjusted rate of heart failure
hospitalization (aHR 0.45, 0.30–0.70) but not ACS or
stroke/TIA (Fig. 1).
In sensitivity analyses excluding AKI-D patients with
pre-existing eGFR ≤24 ml/min/1.73 m2, we obtained similar
crude and adjusted results for death (aHR 0.43, 0.28–0.67)
and heart failure hospitalization (aHR 0.61, 0.27–1.37).
Outcomes between recovery vs. non-recovery from AKI-D
Patients who recovered from AKI-D had lower crude
rates of all-cause death, ACS, and stroke/TIA compared
to those who did not recover (Table 2). In multivariable
analyses, recovery from AKI-D was independently asso-
ciated with lower mortality (aHR 0.70, 0.55–0.88) com-
pared with non-recovery (Fig. 1). However, there were
no significant adjusted differences in rates of heart fail-
ure, ACS, or stroke/TIA (Fig. 1). We obtained similar
crude and adjusted results in our sensitivity analyses
(aHR for death 0.59, 0.44–0.80).
Discussion
Healthy People 2020 includes as key objectives to reduce
all-cause and CVD-related mortality in ESRD patients
[34]. While the U.S. Renal Data System tracks long-term
mortality in ESRD patients, ascertainment of both early
death and CVD events, as well as understanding poten-
tially modifiable risk factors, has been much more challen-
ging. Our study based within a large, community-based
population helps to fill this important knowledge gap.
Our study has several key findings. First, a large fraction
(one third) of incident ESRD patients in our cohort
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Table 1 Baseline characteristics of study cohort. Baseline was defined as pre-hospitalization for patients with dialysis-requiring acute
kidney injury and at the time of dialysis initiation for patients without dialysis-requiring acute kidney injury
Overall ESRD Not Due to AKI-D ESRD Due to AKI-D Recovered AKI-D
Characteristic (n = 6984) (n = 3772) (n = 1865) (n = 1347) P-Value
Age, years, mean (SD) 64.9 (14.0) 64.8 (13.9) 66.7 (13.5) 62.9 (14.7) < 0.001
Female Gender, n (%) 3007 (43.1) 1663 (44.1) 806 (43.2) 538 (39.9) < 0.05
Self-reported Race, n (%)
White/European 2787 (39.9) 1295 (34.3) 763 (40.9) 729 (54.1) < 0.001
Black/African American 1128 (16.2) 638 (16.9) 337 (18.1) 153 (11.4)
Asian/Pacific Islander 1397 (20.0) 911 (24.2) 322 (17.3) 164 (12.2)
Other/Unknown 1672 (23.9) 928 (24.6) 443 (23.8) 301 (22.3)
Hispanic ethnicity, n (%) 1412 (20.2) 821 (21.8) 363 (19.5) 228 (16.9) < 0.001
Smoking status, n (%) < 0.001
Current Smoker 529 (7.6) 228 (6.0) 149 (8.0) 152 (11.3)
Former smoker 2926 (41.9) 1580 (41.9) 809 (43.4) 537 (39.9)
Nonsmoker 3529 (50.5) 1964 (52.1) 907 (48.6) 658 (48.8)
Cardiovascular history, n (%)
Acute myocardial infarction 373 (5.3) 184 (4.9) 135 (7.2) 54 (4.0) < 0.001
Coronary artery bypass graft surgery 111 (1.6) 54 (1.4) 36 (1.9) 21 (1.6) 0.37
Percutaneous coronary intervention 261 (3.7) 128 (3.4) 89 (4.8) 44 (3.3) < 0.05
Heart failure 2162 (31.0) 1092 (29.0) 757 (40.6) 313 (23.2) < 0.001
Ischemic stroke or TIA 323 (4.6) 189 (5.0) 88 (4.7) 46 (3.4) 0.06
Peripheral artery disease 369 (5.3) 264 (7.0) 76 (4.1) 29 (2.2) < 0.001
Mitral and/or aortic valvular disease 721 (10.3) 313 (8.3) 247 (13.2) 161 (12.0) < 0.001
Atrial flutter or fibrillation 943 (13.5) 408 (10.8) 326 (17.5) 209 (15.5) < 0.001
Venous thromboembolism 128 (1.8) 53 (1.4) 37 (2.0) 38 (2.8) < 0.01
Other medical history, n (%)
Diabetes mellitus 4494 (64.3) 2544 (67.4) 1284 (68.8) 666 (49.4) < 0.001
Hypertension 6409 (91.8) 3688 (97.8) 1721 (92.3) 1000 (74.2) < 0.001
Dyslipidemia 5872 (84.1) 3376 (89.5) 1566 (84.0) 930 (69.0) < 0.001
Body mass index, kg/m2, mean (SD) 30.4 (7.7) 29.8 (7.2) 30.8 (8.0) 31.6 (8.5) < 0.001
Systolic blood pressure, mmHg, mean (SD) 134.0 (21.5) 135.8 (20.0) 135.9 (24.1) 126.0 (19.8) < 0.001
Baseline medication use, n (%)
Angiotensin converting enzyme inhibitor 1587 (22.7) 684 (18.1) 441 (23.6) 462 (34.3) < 0.001
Angiotensin II receptor blocker 1110 (15.9) 615 (16.3) 290 (15.5) 205 (15.2) 0.58
Beta blocker 4403 (63.0) 2590 (68.7) 1179 (63.2) 634 (47.1) < 0.001
Calcium channel blocker 3959 (56.7) 2574 (68.2) 1007 (54.0) 378 (28.1) < 0.001
Diuretic 4738 (67.8) 2746 (72.8) 1300 (69.7) 692 (51.4) < 0.001
Alpha blocker 1919 (27.5) 1202 (31.9) 504 (27.0) 213 (15.8) < 0.001
Aldosterone receptor antagonist 272 (3.9) 68 (1.8) 101 (5.4) 103 (7.6) < 0.001
Nitrates 1142 (16.4) 626 (16.6) 396 (21.2) 120 (8.9) < 0.001
Vasodilators 1976 (28.3) 1248 (33.1) 570 (30.6) 158 (11.7) < 0.001
Antiarrhythmic drug 156 (2.2) 55 (1.5) 54 (2.9) 47 (3.5) < 0.001
Statin 4561 (65.3) 2647 (70.2) 1202 (64.5) 712 (52.9) < 0.001
Other lipid-lowering agent 513 (7.3) 294 (7.8) 119 (6.4) 100 (7.4) 0.16
Non-aspirin antiplatelet agent 526 (7.5) 284 (7.5) 160 (8.6) 82 (6.1) < 0.05
Lee et al. BMC Nephrology  (2018) 19:134 Page 4 of 8
developed ESRD via AKI-D. Because we censored patients
who died within 90 days of RRT initiation, one caveat is
that the numbers of incident ESRD patients in both the
AKI-D and non-AKI-D groups were reduced. It can also
be clinically challenging to determine whether patients
with chronic kidney disease who initiate dialysis during a
hospitalization do so because of progression of underlying
disease versus superimposed acute injury. However, prior
single-center and VA data have reported similar propor-
tions of incident ESRD patients initiating dialysis in the
hospital [35–37]. Therefore, our finding that patients with
incident ESRD due to AKI-D have significantly higher ad-
justed all-cause death rates compared to incident ESRD pa-
tients without AKI-D indicates that the large number of
patients who reach ESRD via AKI-D may explain, in part,
the high early mortality rate in the overall ESRD
population.
Second, we found that patients with incident ESRD due
to AKI-D have higher rates of heart failure hospitalization
after RRT initiation than ESRD patients without AKI-D.
These findings extend prior observations that patients
with abrupt decline in renal function before ESRD have
higher rates of heart failure events in the three months be-
fore dialysis initiation compared to those who did not
experience an abrupt decline [20], and patients who initi-
ate dialysis due to volume overload have higher mortality
rates [38]. In our cohort, patients with ESRD due to
AKI-D were more likely to have pre-existing heart failure
compared to patients with ESRD not due to AKI-D. Taken
together, these data suggest that the higher mortality rates
among those who experienced AKI-D leading to ESRD
may be driven, in part, by a greater burden of heart failure.
This finding suggests that better fluid management and
more systematic use of evidence-based therapies for heart
failure may potentially improve outcomes in this vulner-
able population.
Third, our finding that AKI-D patients who recovered
had lower adjusted mortality compared to those who did
not recover highlights yet another reason we urgently
need to devise treatment strategies to enhance or hasten
recovery from AKI-D. Most prior studies evaluating
long-term sequelae after recovery from AKI-D compared
Table 1 Baseline characteristics of study cohort. Baseline was defined as pre-hospitalization for patients with dialysis-requiring acute
kidney injury and at the time of dialysis initiation for patients without dialysis-requiring acute kidney injury (Continued)
Overall ESRD Not Due to AKI-D ESRD Due to AKI-D Recovered AKI-D
Characteristic (n = 6984) (n = 3772) (n = 1865) (n = 1347) P-Value
Low molecular weight heparin 94 (1.3) 28 (0.7) 29 (1.6) 37 (2.7) < 0.001
Non-steroidal anti-inflammatory drug 238 (3.4) 41 (1.1) 71 (3.8) 126 (9.4) < 0.001
Diabetic therapy 2820 (40.4) 1588 (42.1) 796 (42.7) 436 (32.4) < 0.001
Baseline laboratory values
CKD-EPI eGFR, mL/min/1.73 m2
Median (interquartile range) 11.7 (8.4–20.0) 9.8 (7.6–12.4) 14.2 (9.5–24.1) 51.4 (30.6–77.0) < 0.001
Missing, n (%) 392 (5.6) 57 (1.5) 130 (7.0) 205 (15.2)
Urine dipstick proteinuria < 0.001
Negative/Trace 700 (10.0) 218 (5.8) 189 (10.1) 293 (21.8)
1+ 999 (14.3) 515 (13.7) 279 (15.0) 205 (15.2)
≥2+ 4246 (60.8) 2889 (76.6) 1109 (59.5) 248 (18.4)
Unknown 1039 (14.9) 150 (4.0) 288 (15.4) 601 (44.6)
Table 2 Crude rates of all-cause death and cardiovascular
outcomes after dialysis initiation, stratified by end-stage renal
disease (ESRD) and dialysis-requiring acute kidney injury (AKI-D)
status
Outcome Rate per 100 person-years
(95% Confidence Interval)
P-value
All-Cause Death
ESRD due to AKI-D 23.58 (18.06–30.78) Ref
ESRD not due to AKI-D 9.51 (8.50–10.65) < 0.0001
Recovered AKI-D 17.17 (12.78–23.05) 0.0004
Hearth Failure Hospitalization
ESRD due to AKI-D 8.17 (5.09–13.11) Ref
ESRD not due to AKI-D 3.00 (2.45–3.67) < 0.0001
Recovered AKI-D 7.68 (4.66–12.65) 0.5858
Acute Coronary Syndrome
ESRD due to AKI-D 5.14 (3.17–8.33) Ref
ESRD not due to AKI-D 3.45 (2.86–4.17) 0.0081
Recovered AKI-D 2.21 (1.18–4.15) 0.0003
Stroke or Transient Ischemic Attack
ESRD due to AKI-D 3.53 (2.02–6.18) Ref
ESRD not due to AKI-D 2.68 (2.16–3.32) 0.1168
Recovered AKI-D 1.19 (0.54–2.65) 0.0005
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AKI-D patients to matched controls without AKI-D [13,
14], while we were able to distinguish outcome differ-
ences between those who did and did not recover.
Although one small study reported that patients who re-
covered after AKI-D had lower 2-year mortality com-
pared to patients who did not recover after AKI-D, our
cohort was substantially larger and able to account for a
larger set of potential confounders [39].
Finally, although we hypothesized that patients who
recovered after AKI-D would have better outcomes, we
found that even those who are able to discontinue dialy-
sis remain at high risk for cardiovascular events, particu-
larly hospitalizations for heart failure. We examined
early outcomes after RRT initiation because mortality is
particularly high during this time [8] and because AKI-D
may be linked to elevated short-term CVD risk [16].
Several studies in the general population have suggested
a transient increase in risk of stroke or myocardial in-
farction after an episode of infection or systemic inflam-
mation [40, 41], and another study found that
septicemia is a CVD risk factor in ESRD patients [42].
However, we did not find significant differences in out-
comes that may be related to arterial plaque rupture or
occlusion (e.g., ACS, stroke/TIA). Instead, AKI-D lead-
ing to ESRD was most strongly associated with all-cause
death and excess heart failure events, which is also
linked to aberrations in multiple signaling pathways re-
lated to inflammation, fluid overload, myocardial injury,
and ventricular stress [43, 44].
Strengths of our study included the large number of
AKI-D cases, which allowed us to examine the impact of
renal recovery on clinical outcomes. In contrast to the ma-
jority of studies examining highly selected populations
(e.g., post-operative acute kidney injury, contrast-induced
nephropathy) [9], our study included a broad mix of
AKI-D etiologies, which increases generalizability. We
were also able to examine the pre-ESRD disease course
(prior medication use, medical history, and other clinical
features) to characterize incident ESRD subgroups and
add important new insights on the transition to ESRD via
AKI-D as well as the impact of recovery from AKI-D on
CVD outcomes [8, 37, 39, 45, 46]. Furthermore, our data
were much more rigorous than data collected via the
Medical Evidence Report that is used for registration into
the national U.S. Renal Data System [47–50].
Limitations include that some patients classified in our
study as having AKI-D may have initiated dialysis as in-
patients because of progression of advanced chronic kid-
ney disease rather than true AKI-D. However, for the
comparison of patients with ESRD due to vs. not due to
1.00
0.56
0.70
1.00
0.45
1.38
1.00
0.80
0.97
1.00
0.79
0.52
0.10 1.00 10.00
Hazard Ratio (95  CI)
All-cause Death
Heart Failure Hospitalization
Acute Coronary Syndrome
Stroke/Transient Ischemic 
Attack
ESRD due to AKI-D
ESRD not due to AKI-D
Recovered AKI-D
Fig. 1 Multivariable association of all-cause mortality and cardiovascular events after dialysis initiation among patients with incident end-stage
renal disease (ESRD) due to dialysis-requiring acute kidney injury (AKI-D), patients with incident ESRD not due to AKI-D, and patients with AKI-D
who recovered. Models are adjusted for the following baseline covariates: age, gender, race, Hispanic ethnicity, smoking status, acute myocardial
infarction, heart failure, ischemic stroke or transient ischemic attack, peripheral artery disease, mitral and/or aortic valvular disease, atrial flutter or
fibrillation, venous thromboembolism, other thromboembolic events, coronary artery bypass surgery, percutaneous coronary intervention, diabetes
mellitus, hypertension, dyslipidemia, hyperthyroidism, hypothyroidism, cirrhosis, chronic lung disease, diagnosed dementia, diagnosed depression,
hospitalized bleed, body mass index, systolic blood pressure, eGFR, dipstick proteinuria, hemoglobin level, HDL cholesterol level, LDL cholesterol level,
and pre-admission receipt of the following medications: ACE inhibitor, angiotensin II receptor blocker, antiarrhythmic drug, beta blocker, calcium
channel blocker, diuretic, alpha blocker, any anti-hypertensive agent, aldosterone receptor antagonist, nitrates, vasodilators, statin, other lipid-lowering
agent, non-aspirin antiplatelet agent, low molecular weight heparin, non-steroidal anti-inflammatory drug, and diabetic therapy
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AKI-D, this type of misclassification would bias results
toward the null, which bolsters our confidence in the
differences we detected. We did not have details on in-
patient dialysis prescriptions (e.g., modality, dose, or
anticoagulation use), or etiology of AKI-D, including
underlying cardiorenal physiology. Only insured patients
from Northern California enrolled in an integrated
health care delivery system were included, but the KPNC
membership is highly representative of the local
surrounding and statewide population, which argues for
greater generalizability [23]. While we relied on
electronic medical records for key data elements, our
data sources are much more comprehensive than admin-
istrative databases and include clinical data elements
(instead of primarily relying on diagnostic or procedural
codes) [21, 28, 30–32]. Because we wanted to explore
how recovery from AKI-D influences outcomes, we were
only able to compare outcomes that occurred between
90 days after RRT initiation and up to 1 year thereafter.
Conditioning on survival to 90 days (in all three sub-
groups examined) may introduce immortal time bias,
but this potential bias would likely decrease the observed
effect size because the sickest AKI-D patients in the
non-recovery group who died early would be excluded.
We also had to exclude a small number (n = 182) of pa-
tients who were hospitalized for ≥ 90 days during their
AKI-D hospitalization, but again these patients were
likely the sickest AKI-D patients who would have been
at highest risk for early death and CVD events. However,
our design did preclude addressing potential differences
in death and CVD event rates during the first 90 days,
which may be higher as compared to the subsequent
1-year follow-up period.
Conclusions
In conclusion, we found that patients who transition to
ESRD via AKI-D are at higher risk for short-term death
and heart failure hospitalization compared to those who
start chronic dialysis without experiencing AKI-D. Our
findings indicate that the high short-term mortality in
incident ESRD patients may be explained, at least in
part, by the subset of patients who developed ESRD via
AKI-D. Furthermore, our findings suggest that this sub-
set of incident ESRD patients may have worse outcomes
because of pre-existing heart failure. Recovery from
AKI-D was also independently associated with lower
short-term mortality. Collectively, these findings suggest
that aggressive surveillance for and medical management
of heart failure in ESRD patients may be a potential
strategy for reducing early mortality after AKI-D.
Further studies are warranted to evaluate whether pro-
motion of renal recovery from AKI-D and systematic
surveillance and intervention for heart failure can im-
prove outcomes in this vulnerable patient population.
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